#United States #Minneapolis #Neuromodulation #Avivomed #Dan Brounstein

Avivomed Announces Dan Brounstein as New CEO

Avivomed, a clinical-stage medical device company, has appointed Dan Brounstein as its new Chief Executive Officer, succeeding Steve Masson, who retired earlier this year. With over 30 years of experience in the medical device industry, Brounstein is expected to spearhead Avivomed's mission to develop pioneering neuromodulation therapies that improve the quality of life for patients suffering from conditions such as obstructive sleep apnea.

The Vision Ahead

Avivomed aims to address the critical need for effective solutions in treating sleep disorders, which affect millions around the world. Current therapies often have limitations, and Avivomed is determined to break through these barriers with innovative treatments. Dr. Mudit K. Jain, Co-founder and Chair of Avivomed’s Board of Directors, highlighted Brounstein's background in neuromodulation and leadership in launching advanced medical therapies. His appointment comes at a pivotal time as the company strives to bring new and effective solutions to market.

Dan Brounstein's Remarkable Background

Brounstein's experience includes significant leadership roles in established medical device firms. Prior to joining Avivomed, he led efforts at Saluda Medical as Chief Strategy Officer, where he was instrumental in the landmark Evoke Pivotal Study and the launch of the Evoke ECAP-Controlled, Closed-Loop Spinal Cord Stimulator. His previous positions also include Vice President of Marketing and Clinical Operations at Spinal Modulation, where he played a crucial role in the strategy that led to the successful market introduction of DRG Stimulation, culminating in the acquisition by St. Jude Medical, now known as Abbott.

With a Bachelor of Science in Bioengineering obtained from UC San Diego and an MBA from the University of California, Berkeley's Haas School of Business, Brounstein's educational foundation complements his extensive professional expertise.

A Bright Future for Avivomed

As Avivomed embarks on its journey with Brounstein at the helm, the company can capitalize on the NuXcel innovation ecosystem, which supports its vision for developing next-generation, minimally invasive neuromodulation therapies. Avivomed is based in Minneapolis and has garnered backing from notable investors, including F-Prime, Hatteras Venture Partners, and Norwest.

With a strong leadership team and a clear mission, Avivomed is poised to make significant strides in the field of sleep medicine, potentially transforming treatment options for countless patients struggling with interrupted sleep and other related disorders.

Stay tuned for further developments as Dan Brounstein leads Avivomed into this exciting new chapter in health care innovation.